Valute / ACAD
ACAD: ACADIA Pharmaceuticals Inc
25.99
USD
0.24
(0.91%)
Il tasso di cambio ACAD ha avuto una variazione del -0.91% per oggi. Durante la giornata, lo strumento è stato scambiato ad un minimo di 25.82 e ad un massimo di 26.30.
Segui le dinamiche di ACADIA Pharmaceuticals Inc. Le quotazioni in tempo reale aiutano a reagire velocemente alle variazioni di mercato. Scorrendo tra i diversi timeframe, è possibile monitorare le tendenze e le dinamiche dei tassi di cambio di minuti, ore, giorni, settimane e mesi. Utilizza queste informazioni per prevedere i cambiamenti del mercato e prendere decisioni di trading consapevoli.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
ACAD News
- Axsome Shares Up 20% in a Month: How Should You Play the Stock?
- Acadia Pharmaceuticals appoints Katcheves as chief business officer
- Acadia Pharmaceuticals stock hits 52-week high at $25.90
- JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
- Mizuho lowers Acadia Pharmaceuticals stock price target to $22 from $32
- Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD
- Acadia Pharmaceuticals stock price target raised to $24 from $18 at Stifel
- Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
- Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings
- Acadia Pharmaceuticals stock price target raised to $38 from $37 at Citizens JMP
- Acadia Pharmaceuticals Q2 2025 slides: revenue up 9%, raises full-year guidance
- Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates
- Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
- Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
- Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
- Sarepta to Report Q2 Earnings: What's in Store for the Stock?
- GMAB vs. ACAD: Which Stock Is the Better Value Option?
- Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
- ACADIA Pharmaceutical: ACP-101 Read-Out Is Not Fully Priced In (NASDAQ:ACAD)
- Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
- Acadia stock price target raised to $32 from $22 at UBS on growth outlook
- Acadia Pharmaceuticals stock rating reiterated by H.C. Wainwright
- Acadia stock maintains outperform rating at RBC on pipeline potential
- Acadia Pharmaceuticals stock maintains outperform rating at BMO Capital
Intervallo Giornaliero
25.82
26.30
Intervallo Annuale
13.40
26.64
- Chiusura Precedente
- 26.23
- Apertura
- 26.19
- Bid
- 25.99
- Ask
- 26.29
- Minimo
- 25.82
- Massimo
- 26.30
- Volume
- 2.026 K
- Variazione giornaliera
- -0.91%
- Variazione Mensile
- 9.66%
- Variazione Semestrale
- 32.00%
- Variazione Annuale
- 57.04%
30 agosto, sabato